BALTIMORE, MD / ACCESS Newswire / January 30, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on OKYO Pharma Limited (NASDAQ:OKYO), an emerging player in the fast-growing ophthalmic drugs segment. The Goldman report carries a price target. To view the new research report, along with disclosures and disclaimers, or to download the report in its entirety, please visit: https://goldmansmallcapresearch.com/opportunity-research/innovative-okyo-pharma-has-first-mover-advantage/
Tracing its roots to 2018, OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain (NCP) and inflammatory dry eye disease (DED). Its lead drug candidate OK-101 successfully completed a 240-patient Phase 2 trial in DED patients and is also currently being evaluated in a 48-patient, randomized, placebo-controlled Phase 2 trial in NCP patients that seeks to demonstrate OK-101's ability to reduce neuropathic corneal pain. If an award of orphan drug designation to NCP, should happen, it could lead to a multi-billion dollar market opportunity for OKYO.
In the Opportunity Research report, analyst Rob Goldman reviews clinical and preclinical data on OKYO's lead candidate, the Company's inherent first-mover opportunities in the industry, upcoming milestones and how these milestones and the flurry of M&A in the segment can favorably impact OKYO's near term and long term valuations.
Innovative BioPharma Set to Leverage Unique Product Positioning
Goldman commented, "In our view, OKYO is uniquely positioned to emerge as a key player in the ocular treatment arena. OKYO Pharma is focused on developing OK-101 to treat NCP which presently has no FDA approved drug to treat this debilitating ocular disease. OKYO Pharma commenced its Phase 2 trial of OK-101 in October 2024 and results are expected by year-end 2025."
A Series of Firsts
"OKYO is the first company to be granted an investigational new drug (IND) application for NCP by the FDA for clinical trials in NCP patients, and the first company to launch a clinical trial in NCP patients specifically diagnosed with NCP. This trial is on the heels of a favorable DED Phase 2 trial of OK-101 which notably demonstrated statistical significance in an ocular pain secondary endpoint," noted Goldman.
Substantial Potential Opportunity
"Based on our estimates, the potential size of the NCP market assuming NCP receives Orphan Drug designation, is $6.4 billion", stated Goldman. "The market opportunity for the first drug to receive FDA approval to treat this major unmet medical need is based on a 160,000 US potential patient size."
Upcoming Milestones, 12-Month Price Target, Future Valuations
"We believe that given its positioning, and assuming data are favorable, OKYO could attract a potential joint venture development partner or a future acquirer in 2026/2027. We believe that a series of milestones in 2025 followed by results from this trial serve as major catalysts for a re-valuation of these shares. Our 12-month piece target is based on the prospective value of OK-101, projected sales multiples, and the median valuation of ocular biopharma M&A transactions," concluded Goldman.
About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters.
Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
This press release contains excerpts of our most recently published company report on OKYO Pharma Limited ("The Company"). The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from OKYO Pharma Limited. The information includes authorized press releases or legal disclosures made in their filings with the U.S. Securities and Exchange Commission http://www.sec.gov.
Separate from the factual content of our update about the Company, we may from time to time include our own opinions about the Company, its business, markets, and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
A Goldman Small Cap Research report, update, newsletter, article, trading alert, corporate profile, sector or industry snapshot, podcast interview, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other regulatory agency. To download this research report visit www.goldmansmallcapresearch.com. Goldman Small Cap Research was compensated by the Company in the amount of $4000 for a research report production and distribution, including a press release. In 2023, Goldman Small Cap Research (GSCR) was compensated by a third party (TraDigital Marketing Group, Inc.) in the amount of $4000 for research report production and a press release.
Goldman Small Cap Research
Rob Goldman, Analyst
410-800.7980
rob@goldmansmallcapresearch.com
SOURCE: Goldman Small Cap Research
View the original press release on ACCESS Newswire
